The author reflects on the patent filled by Myriad genetics for the diagnostic genetic testing of the two sequence of the breast cancer genes including BRCA1 and BRCA2 and also for the determination of the determine cancer risk. He discusses the diagnostic sequencing for the disorders. He also mentions an overview on the patent law for the diagnosis of Down syndrome.